Relationship between single oral dose pharmacokinetics of alprazolam and triazolam

被引:7
作者
Otani, K
Yasui, N
Furukori, H
Kaneko, S
Tasaki, H
Ohkubo, T
Nagasaki, T
Sugawara, K
Hayashi, K
机构
[1] HIROSAKI UNIV HOSP,DEPT PHARM,HIROSAKI,AOMORI 036,JAPAN
[2] GOSHOGAWARA CITY HOSP,DEPT PHARM,GOSHOGAWARA 037,JAPAN
[3] GUNMA UNIV,SCH HLTH SCI,DEPT ALLIED MED SCI,MAEBASHI,GUMMA 371,JAPAN
关键词
alprazolam; pharmacokinetics; single oral dose; triazolam;
D O I
10.1097/00004850-199705000-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The relationship between the single oral dose pharmacokinetics of alprazolam and triazolam was studied in 10 healthy male volunteers. Each subject took single oral doses of alprazolam 0.8 mg and triazolam 0.5 mg with at least a 2 week interval between each dose. Blood samplings were performed up to 48 h after alprazolam dosing and up to 12 h after triazolam dosing. Plasma concentrations of both drugs were measured by high-performance liquid chromatography. The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11.3 +/- 3.1 ng/ml, 232.3 +/- 59.2 ng/h/ml and 16.5 +/- 4.6 h, respectively, and those of triazolam were 3.2 +/- 1.0 ng/ml, 11.8 +/- 5.2 ng/h/ml and 2.5 +/- 1.1 h, respectively. There was no significant correlation between the two drugs in any pharmacokinetic parameters (r = 0.35, 0.25 and 0.50). The present study thus suggests that the single oral dose pharmacokinetics of alprazolam and triazolam do not correlate well in individuals.
引用
收藏
页码:153 / 157
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 2007, Biostatistical analysis
[2]   THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, AND PARACETAMOL AS PROBES [J].
BOCK, KW ;
SCHRENK, D ;
FORSTER, A ;
GRIESE, EU ;
MORIKE, K ;
BROCKMEIER, D ;
EICHELBAUM, M .
PHARMACOGENETICS, 1994, 4 (04) :209-218
[3]  
FLEISHAKER JC, 1994, EUR J CLIN PHARMACOL, V46, P35
[4]   PHARMACOKINETICS OF THE NEWER BENZODIAZEPINES [J].
GARZONE, PD ;
KROBOTH, PD .
CLINICAL PHARMACOKINETICS, 1989, 16 (06) :337-364
[5]   SENSITIVITY TO TRIAZOLAM IN THE ELDERLY [J].
GREENBLATT, DJ ;
HARMATZ, JS ;
SHAPIRO, L ;
ENGELHARDT, N ;
GOUTHRO, TA ;
SHADER, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (24) :1691-1698
[6]   CLINICAL PHARMACOKINETICS OF ALPRAZOLAM - THERAPEUTIC IMPLICATIONS [J].
GREENBLATT, DJ ;
WRIGHT, CE .
CLINICAL PHARMACOKINETICS, 1993, 24 (06) :453-471
[7]   Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine [J].
Jeppesen, U ;
Gram, LF ;
Vistisen, K ;
Loft, S ;
Poulsen, HE ;
Brosen, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) :73-78
[8]  
KRONBACH T, 1989, MOL PHARMACOL, V36, P89
[9]  
LOWN KS, 1994, DRUG METAB DISPOS, V22, P947
[10]   LACK OF INFLUENCE OF CIGARETTE-SMOKING ON TRIAZOLAM PHARMACOKINETICS [J].
OCHS, HR ;
GREENBLATT, DJ ;
BURSTEIN, ES .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (06) :759-763